Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. (Q37794960)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883052%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883052%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883052%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Giuseppe Derosa

series ordinal

1

1 reference

23 August 2017

1 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883052%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883052%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883052%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883052%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

1945-1961

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883052%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/11538100-000000000-00000

14 February 2020

exact match

0 references

cites work

Glycemia management and cardiovascular risk in type 2 diabetes: an evolving perspective

1 reference

https://api.crossref.org/works/10.2165%2F11538100-000000000-00000

Pioglitazone has anti-inflammatory effects in patients with Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538100-000000000-00000

Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538100-000000000-00000

Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538100-000000000-00000

High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538100-000000000-00000

Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538100-000000000-00000

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11538100-000000000-00000

2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration

21 January 2018

1 reference

12 December 2020

Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide

1 reference

12 December 2020

Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide

1 reference

12 December 2020

Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital.

1 reference

12 December 2020

Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial

1 reference

12 December 2020

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

1 reference

12 December 2020

Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus.

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

12 December 2020

Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes

1 reference

12 December 2020

Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions

1 reference

12 December 2020

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

1 reference

12 December 2020

Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis

1 reference

12 December 2020

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

1 reference

12 December 2020

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

12 December 2020

A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

1 reference

12 December 2020

Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients

1 reference

12 December 2020

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

12 December 2020

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

1 reference

12 December 2020

Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy

1 reference

12 December 2020

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

1 reference

12 December 2020

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).

1 reference

12 December 2020

Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study

1 reference

12 December 2020

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

1 reference

12 December 2020

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients

1 reference

12 December 2020

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

1 reference

12 December 2020

Advances in diabetes for the millennium: drug therapy of type 2 diabetes

1 reference

12 December 2020

Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone

1 reference

12 December 2020

Thiazolidinediones and the liver in humans

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes

1 reference

12 December 2020

Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease

1 reference

12 December 2020

Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes

1 reference

12 December 2020

Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial

1 reference

12 December 2020

Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment.

1 reference

12 December 2020

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

1 reference

12 December 2020

Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes

1 reference

12 December 2020

Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial

1 reference

12 December 2020

Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study

1 reference

12 December 2020

Pioglitazone: mechanism of action.

1 reference

12 December 2020

Effects of thiazolidinediones on bone loss and fracture

1 reference

12 December 2020

Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study

1 reference

12 December 2020

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

1 reference

12 December 2020

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

1 reference

12 December 2020

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

12 December 2020

Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine

1 reference

12 December 2020

New drugs for type 2 diabetes mellitus: what is their place in therapy?

1 reference

12 December 2020

Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones.

1 reference

12 December 2020

Thiazolidinedione-associated congestive heart failure and pulmonary edema

1 reference

12 December 2020

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

1 reference

12 December 2020

Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes.

1 reference

12 December 2020

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

1 reference

12 December 2020

The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.

1 reference

12 December 2020

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.

1 reference

12 December 2020

Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes

1 reference

12 December 2020

Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin.

1 reference

12 December 2020

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome

1 reference

12 December 2020

Metformin in heart failure

1 reference

12 December 2020

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, para

1 reference

12 December 2020

Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes

1 reference

12 December 2020

Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.

1 reference

12 December 2020

Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients

1 reference

12 December 2020

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

12 December 2020

Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes

1 reference

12 December 2020

Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus

1 reference

12 December 2020

Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.

1 reference

12 December 2020

Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone

1 reference

12 December 2020

Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes

1 reference

12 December 2020

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

1 reference

12 December 2020

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

1 reference

12 December 2020

Thiazolidinediones improve beta-cell function in type 2 diabetic patients.

1 reference

12 December 2020

Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.

1 reference

12 December 2020

Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin

1 reference

12 December 2020

Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects

1 reference

12 December 2020

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

1 reference

12 December 2020

Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes

1 reference

12 December 2020

Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus

1 reference

12 December 2020

A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes

1 reference

12 December 2020

Bone is a target for the antidiabetic compound rosiglitazone.

1 reference

12 December 2020

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation

1 reference

12 December 2020

Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone

1 reference

12 December 2020

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

1 reference

12 December 2020

Standards of medical care in diabetes--2010.

1 reference

12 December 2020

Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).

1 reference

12 December 2020

Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study

1 reference

12 December 2020

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes

1 reference

12 December 2020

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

12 December 2020

Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17).

1 reference

12 December 2020

Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens

1 reference

12 December 2020

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial

1 reference

12 December 2020

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

12 December 2020

Renal and vascular mechanisms of thiazolidinedione-induced fluid retention

1 reference

12 December 2020

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

1 reference

12 December 2020

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

1 reference

12 December 2020

Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study

1 reference

12 December 2020

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

1 reference

12 December 2020

Coefficient of beta-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose

1 reference

12 December 2020

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

12 December 2020

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

12 December 2020

Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes

1 reference

12 December 2020

Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.

1 reference

12 December 2020

Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy

1 reference

12 December 2020

Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes

1 reference

12 December 2020

Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients

1 reference

12 December 2020

Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes

1 reference

12 December 2020

Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study

1 reference

12 December 2020

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

1 reference

12 December 2020

Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes

1 reference

12 December 2020

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

12 December 2020

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

1 reference

12 December 2020